Literature DB >> 25868759

Effects of Dry Eye Therapies on Environmentally Induced Ocular Surface Disease.

Quianta L Moore1, Cintia S De Paiva1, Stephen C Pflugfelder2.   

Abstract

PURPOSE: To evaluate the effectiveness of artificial tears and corticosteroids on mitigating the acute ocular surface response to low-humidity environments.
DESIGN: Single-group, crossover clinical trial.
METHODS: Twenty subjects with aqueous deficient dry eye were enrolled. Subjects meeting inclusion criteria at visit 1 were exposed to a baseline 90-minute low-humidity environment at visit 2. They then used artificial tears for 2 weeks prior to low-humidity exposure at visit 3, followed by 0.1% dexamethasone for 2 weeks prior to the final low-humidity exposure at visit 4. Outcome measures included corneal and conjunctival staining, blink rate, and irritation symptoms before and after each low-humidity exposure. Digital polymerase chain reaction (PCR) was performed to measure HLA-DR RNA transcripts in conjunctival cells taken by impression cytology at each visit.
RESULTS: There was significantly less corneal and conjunctival epitheliopathy after the low-humidity exposure at visit 4 compared to after the low-humidity exposure at visit 3 (P = .003). Subjects reported significantly less eye irritation during the low-humidity exposure after using the dexamethasone (visit 4) compared to artificial tears (visit 3) (P = .01). HLA-DR transcripts significantly decreased after the stress at visit 4 (post dexamethasone) compared to visit 2.
CONCLUSION: Our study demonstrates that corticosteroid eye drops mitigate the acute adverse effects of an experimental low-humidity challenge, likely owing to suppression of stress-activated inflammatory pathways. While extended use of corticosteroids is not indicated, other anti-inflammatory therapies with activity against stress-activated pathways may prove as effective.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25868759      PMCID: PMC4464943          DOI: 10.1016/j.ajo.2015.04.008

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  37 in total

1.  Comparison of the clinical effects of carbomer-based lipid-containing gel and hydroxypropyl-guar gel artificial tear formulations in patients with dry eye syndrome: a 4-week, prospective, open-label, randomized, parallel-group, noninferiority study.

Authors:  Tsung-Jen Wang; I-Jong Wang; Jau-Der Ho; Hsiu-Chu Chou; Szu-Yuan Lin; Man-Ching Huang
Journal:  Clin Ther       Date:  2010-01       Impact factor: 3.393

2.  American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort.

Authors:  S C Shiboski; C H Shiboski; L A Criswell; A N Baer; S Challacombe; H Lanfranchi; M Schiødt; H Umehara; F Vivino; Y Zhao; Y Dong; D Greenspan; A M Heidenreich; P Helin; B Kirkham; K Kitagawa; G Larkin; M Li; T Lietman; J Lindegaard; N McNamara; K Sack; P Shirlaw; S Sugai; C Vollenweider; J Whitcher; A Wu; S Zhang; W Zhang; J S Greenspan; T E Daniels
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-04       Impact factor: 4.794

3.  Immunophenotyping of human dendriform cells from the conjunctival epithelium.

Authors:  C Baudouin; F Brignole; P J Pisella; F Becquet; P J Philip
Journal:  Curr Eye Res       Date:  1997-05       Impact factor: 2.424

4.  Factors predicting the ocular surface response to desiccating environmental stress.

Authors:  Anastasia Alex; Austin Edwards; J Daniel Hays; Michelle Kerkstra; Amanda Shih; Cintia S de Paiva; Stephen C Pflugfelder
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-05-07       Impact factor: 4.799

5.  Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A.

Authors:  F Brignole; P J Pisella; M De Saint Jean; M Goldschild; A Goguel; C Baudouin
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-01       Impact factor: 4.799

Review 6.  Rethinking dry eye disease: a perspective on clinical implications.

Authors:  Anthony J Bron; Alan Tomlinson; Gary N Foulks; Jay S Pepose; Christophe Baudouin; Gerd Geerling; Kelly K Nichols; Michael A Lemp
Journal:  Ocul Surf       Date:  2014-02-13       Impact factor: 5.033

7.  HLA-DR expression as a biomarker of inflammation for multicenter clinical trials of ocular surface disease.

Authors:  Seth P Epstein; Neha Gadaria-Rathod; Yi Wei; Maureen G Maguire; Penny A Asbell
Journal:  Exp Eye Res       Date:  2013-04-06       Impact factor: 3.467

8.  Dry eye disease and work productivity loss in visual display users: the Osaka study.

Authors:  Miki Uchino; Yuichi Uchino; Murat Dogru; Motoko Kawashima; Norihiko Yokoi; Aoi Komuro; Yukiko Sonomura; Hiroaki Kato; Shigeru Kinoshita; Debra A Schaumberg; Kazuo Tsubota
Journal:  Am J Ophthalmol       Date:  2013-11-01       Impact factor: 5.258

Review 9.  Dry eye as a mucosal autoimmune disease.

Authors:  Michael E Stern; Chris S Schaumburg; Stephen C Pflugfelder
Journal:  Int Rev Immunol       Date:  2013-02       Impact factor: 5.311

10.  A prospective, multicenter, noninterventional study of Optive Plus(®) in the treatment of patients with dry eye: the prolipid study.

Authors:  Thomas Kaercher; Ulrich Thelen; Gerrett Brief; Robert J Morgan-Warren; Richard Leaback
Journal:  Clin Ophthalmol       Date:  2014-06-17
View more
  13 in total

Review 1.  Update on the role of impression cytology in ocular surface disease.

Authors:  Zhang-Zhe Thia; Louis Tong
Journal:  Taiwan J Ophthalmol       Date:  2019-09-12

2.  What We Have Learned From Animal Models of Dry Eye.

Authors:  Michael E Stern; Stephen C Pflugfelder
Journal:  Int Ophthalmol Clin       Date:  2017

3.  Interferon-γ-Induced Unfolded Protein Response in Conjunctival Goblet Cells as a Cause of Mucin Deficiency in Sjögren Syndrome.

Authors:  Terry G Coursey; Johanna Tukler Henriksson; Flavia L Barbosa; Cintia S de Paiva; Stephen C Pflugfelder
Journal:  Am J Pathol       Date:  2016-04-13       Impact factor: 4.307

4.  Aqueous Tear Deficiency Increases Conjunctival Interferon-γ (IFN-γ) Expression and Goblet Cell Loss.

Authors:  Stephen C Pflugfelder; Cintia S De Paiva; Quianta L Moore; Eugene A Volpe; De-Quan Li; Koray Gumus; Mahira L Zaheer; Rosa M Corrales
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-11       Impact factor: 4.799

Review 5.  Sjögren syndrome: what and where are we looking for?

Authors:  Cintia S de Paiva; Eduardo Melani Rocha
Journal:  Curr Opin Ophthalmol       Date:  2015-11       Impact factor: 3.761

Review 6.  The Pathophysiology of Dry Eye Disease: What We Know and Future Directions for Research.

Authors:  Stephen C Pflugfelder; Cintia S de Paiva
Journal:  Ophthalmology       Date:  2017-11       Impact factor: 12.079

Review 7.  The Growing Need for Validated Biomarkers and Endpoints for Dry Eye Clinical Research.

Authors:  Neeta S Roy; Yi Wei; Eric Kuklinski; Penny A Asbell
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-05-01       Impact factor: 4.799

8.  Custom RT-qPCR-array for glaucoma filtering surgery prognosis.

Authors:  Iñaki Rodriguez-Agirretxe; Iker Garcia; Javier Soria; Tatiana Maria Suarez; Arantxa Acera
Journal:  PLoS One       Date:  2017-03-30       Impact factor: 3.240

9.  Dry eye in rheumatoid arthritis patients under TNF-inhibitors: conjunctival goblet cell as an early ocular biomarker.

Authors:  Fany Solange Usuba; Ana Cristina de Medeiros-Ribeiro; Priscila Novaes; Nadia Emi Aikawa; Karina Bonfiglioli; Ruth Miyuki Santo; Eloisa Bonfá; Milton Ruiz Alves
Journal:  Sci Rep       Date:  2020-08-20       Impact factor: 4.379

10.  Improvement of conjunctival cytological grade and tear production in Ankylosing Spondylitis patients under TNF inhibitors: a long-term follow-up.

Authors:  Fany Solange Usuba; Carla Gonçalves Schahin Saad; Nadia Emi Aikawa; Priscila Novaes; Julio Cesar Bertacini Moraes; Ruth Miyuki Santo; Jozelio Freire Carvalho; Eloisa Bonfá; Milton Ruiz Alves
Journal:  Sci Rep       Date:  2020-01-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.